Please login to the form below

Not currently logged in
Email:
Password:

India passes clinical trials compensation law

Pharma sponsors will need to pay in cases of trial-related injuries and deaths

India has amended its clinical trials laws, adding new rules that will oblige pharma companies sponsoring trials to pay compensation in cases where volunteers suffer trial-related death or injury.

The Ministry of Health & Family Welfare ruling comes a month after the Supreme Court of India, based in New Delhi, criticised the country's government for poor regulation of clinical trials.

Compensation will be decided on a case-by-case basis, according to a local report in The Economic Times, and failure to pay up could see pharma firms and clinical research organisations (CROs) face suspension of trials and even a permanent ban on their activities.

However, the Indian Society of Clinical Research (ISCR) criticised sections of the new amendment on compensation, which they believe will have "a far-reaching impact on organisations and academic institutes, both Indian and multination".

The ISCR said: "The clauses stating that compensation needs to be paid for injury or death due to failure of investigational product to provide intended therapeutic effect and use of placebo in placebo controlled trials contradict the scientific base of a clinical trial."

The institute added: "It is ironical that the Ministry notification has come around the same time that the US FDA is holding a hearing to discuss with industry experts how a speedier pathway to approve drugs and biologics for serious and life-threatening conditions with unmet medical needs can be constructed."

7th February 2013

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics